Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Fuji
US Department of Justice
Cantor Fitzgerald
Boehringer Ingelheim
Chinese Patent Office
Medtronic
AstraZeneca
Dow
UBS

Generated: October 22, 2017

DrugPatentWatch Database Preview

ZYPREXA RELPREVV Drug Profile

« Back to Dashboard

What is the patent landscape for Zyprexa Relprevv, and what generic Zyprexa Relprevv alternatives are available?

Zyprexa Relprevv is a drug marketed by Eli Lilly Co and is included in one NDA. There is one patent protecting this drug.

This drug has seventy-one patent family members in thirty-one countries and three supplementary protection certificates in three countries.

The generic ingredient in ZYPREXA RELPREVV is olanzapine pamoate. There are thirty-three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the olanzapine pamoate profile page.

Summary for Tradename: ZYPREXA RELPREVV

US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list93
Clinical Trials: see list36
Patent Applications: see list12
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ZYPREXA RELPREVV at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly Co
ZYPREXA RELPREVV
olanzapine pamoate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022173-001Dec 11, 2009RXYesNo► Subscribe► SubscribeYY ► Subscribe
Eli Lilly Co
ZYPREXA RELPREVV
olanzapine pamoate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022173-002Dec 11, 2009RXYesNo► Subscribe► SubscribeYY ► Subscribe
Eli Lilly Co
ZYPREXA RELPREVV
olanzapine pamoate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022173-003Dec 11, 2009RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ZYPREXA RELPREVV

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eli Lilly Co
ZYPREXA RELPREVV
olanzapine pamoate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022173-001Dec 11, 2009► Subscribe► Subscribe
Eli Lilly Co
ZYPREXA RELPREVV
olanzapine pamoate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022173-003Dec 11, 2009► Subscribe► Subscribe
Eli Lilly Co
ZYPREXA RELPREVV
olanzapine pamoate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022173-002Dec 11, 2009► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ZYPREXA RELPREVV

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,617,321 2-methyl-thieno-benzodiazepine formulation► Subscribe
7,303,7642-methyl-thieno-benzodiazepine formulation► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ZYPREXA RELPREVV

Country Document Number Estimated Expiration
New Zealand503641► Subscribe
Eurasian Patent Organization002580► Subscribe
Turkey200000812► Subscribe
Australia3362799► Subscribe
Canada2304568► Subscribe
Hong Kong1041199► Subscribe
Portugal1119359► Subscribe
Eurasian Patent Organization200000381► Subscribe
Japan4503826► Subscribe
Ukraine66872► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ZYPREXA RELPREVV

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB96/058United Kingdom► SubscribePRODUCT NAME: OLANZAPINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/96/022/001 19960927; UK EU/1/96/022/002 19960927; UK EU/1/96/022/003 19960927; UK EU/1/96/022/004 19960927; UK EU/1/96/022/005 19960927; UK EU/1/96/022/006 19960927; UK EU/1/96/022/007 19960927; UK EU/1/96/022/008 19960927; UK EU/1/96/022/009 19960927; UK EU/1/96/022/010 19960927
C0012Belgium► SubscribePRODUCT NAME: OLANZAPINE; REGISTRATION NO/DATE: EU/1/96/022/001 19960927
70015Netherlands► SubscribePRODUCT NAME: OLANZAPINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT; REGISTRATION NO/DATE: EU/1/96/022/001 - EU/1/96/022/010 19960927
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
UBS
Johnson and Johnson
QuintilesIMS
Express Scripts
Dow
Fuji
Harvard Business School
US Department of Justice
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot